AbbVie leverages a strong specialty drug portfolio to offset the loss of exclusivity for its former

Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications

BNP Paribas analyst Navann Ty maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price ta

Both of these stocks pay more than double the S&P 500 average of 1.1%.

AbbVie has been willing to supplement its new drug pipeline through acquisitions. It plans to pay $1

Contravisory Investment Management Inc. reduced its stake in shares of AbbVie Inc. (NYSE: ABBV) by 7

Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and

About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays

AbbVie's growth rate was more than 10% this past quarter and has been rising in recent years. Its va

Year to date, the healthcare sector finds itself in the middle of the S&P 500's pack.

Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the an

AbbVie relies on a high-margin biopharmaceutical portfolio and significant free cash flow to drive s

ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results,

Bill Few Associates Inc. decreased its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 9.4% during

Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 m

There is no end in sight for the drugmaker's dividend growth streak.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or H

I'm going to put our year-end call on the table before anything else. Our AbbVie (NYSE:ABBV | ABBV P

BDF Gestion reduced its position in shares of AbbVie Inc. (NYSE: ABBV) by 10.1% during the undefined

Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the U.S. Food and Drug Administr

If approved, BOTOX ® Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price targe

UBRELVY® (ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC) is supported by

Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the pri

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation

AbbVie raises 2026 revenue guidance on Skyrizi, Rinvoq and neuroscience growth, while the Apogee dea

On June 29, AbbVie Inc. stock reached a 52-week high of $267.47. But over the past five days, its sh

Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises

Your portfolio could be paying you quarterly income right now from three companies that have raised

First National Bank of Mount Dora Trust Investment Services lessened its holdings in shares of AbbVi

It posted a second-quarter earnings report that raised some concerns. One was a miss on the consensu

AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript

Release Date: July 31, 2026For the complete transcript of the earnings call, please refer to the ful

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.65% on an annualized basis

Amazon surges 15% on an AWS blowout while Apple sheds nearly $475 billion in value. Yields sit at cy

Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX s

AbbVie (NYSE:ABBV) is looking for Q3 Adj EPS of $3.84-$3.88 vs $3.84 analyst estimate. sees sales of

AbbVie Inc. (NYSE: ABBV) shares are retreating Friday after trimming full-year adjusted EPS guidance

AbbVie (NYSE:ABBV) reported quarterly earnings of $3.65 per share which beat the analyst consensus e

Barclays analyst Emily Field maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price

Scott warns China’s new drug rules could threaten U.S. medicine security, urging America to reduce r

RINVOQ is the first and only systemic medication approved in the European Union to treat adult and a

AbbVie shares gained 1.4% to close at $256.92 on Thursday while Transocean shares rose 0.4% to settl

Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up t

Top analysts change outlook on top names. Baird, Canaccord Genuity, Needham, Stifel, Truist Securiti

Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the pri

REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alo

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.69% on an annualized basi

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the European Commission has approved

UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp d